REXAHN PHARMACEUTICALS, INC DEF 14A 6-10-2013

Company

Opus Genetics, Inc.

Filed

April 22, 2013

Period of Report

June 10, 2013

Accession Number

0001140361-13-017009

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →